Glenmark Pharmaceuticals Limited — Updates, 27-02-2025: Press Release

Glenmark Pharmaceuticals Inc. has launched its Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial, marking a significant addition to its product portfolio in the U.S. The product is bioequivalent to BPI Labs’ reference drug and is eligible for 180 days of CGT exclusivity. The Epinephrine market generated annual sales of approximately $42.7 million for the year ending December 2024, indicating a strong market presence and demand. This launch diversifies Glenmark’s offerings within the institutional channel, reinforcing its commitment to providing quality, affordable alternatives for patients. Investors should monitor the ongoing performance in this segment, as it presents potential growth opportunities amidst a competitive landscape.